Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/ IB Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in KRAS

Summary

The purpose of this study is to evaluate the safety and feasibility of RMC- 6236 in adults with KRAS p.G12 mutant advanced solid tumors, including pancreatic cancer.

General Information

NCT#: NCT05379985
Study ID: RMC-6236-001
Trial Phase: Phase I

Trial Sponsor: Revolution Medicines, Inc.
Therapies Used in This Trial: RMC- 6236

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search